Valiant Co.,Ltd

Valiant Co.,Ltd., a global enterprise established in 1992, specializes in the worldwide production and distribution of an extensive array of chemical materials. The company's diverse product portfolio primarily encompasses electronic chemicals, including components and intermediates vital for liquid crystal displays (LCDs) and organic light-emitting diodes (OLEDs), as well as polyimide (PI) materials, photoresist (PR) monomers, and crucial additives for lithium-ion batteries. Beyond electronics, Valiant provides various specialized materials for environmental and industrial applications. These include substances for automotive exhaust purification, catalysts for flue gas denitrification, volatile organic compound (VOC) adsorption, methanol-to-olefin conversion, and petroleum cracking. Furthermore, the company contributes to the new energy sector with advanced materials, energy-efficient lighting solutions, organic solar technologies, and ancillary components for electric vehicles. Valiant's operations also extend into the life sciences and healthcare domains. It manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and finished drug formulations, alongside traditional Chinese medicine products and nutritional health supplements. The company supports scientific research through life science products and services relevant to drug innovation, genomics, proteomics, metabolomics, and food health analysis. Additionally, Valiant develops diagnostic reagents essential for identifying human diseases such as AIDS, hepatitis, cancer, dengue fever, and cardiovascular/cerebrovascular conditions, as well as for detecting drug abuse, endocrine levels, and other physiological parameters. Originally known as Yantai Valiant Fine Chemicals Co., Ltd., the company rebranded to Valiant Co.,Ltd. in May 2015. It is headquartered in Yantai, China.

Valiant Co.,Ltd trades as 002643.SZ on SHZ. The company is classified in Basic Materials / Chemicals and reports in CNY.

The current profile places the business in Chemicals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Valiant Co.,Ltd can be compared against peers such as YOUNGY Co.,Ltd., North Chemical Industries Co., Ltd., Shanghai Pret Composites Co., Ltd., Yantai Dongcheng Pharmaceutical Group Co.,Ltd., PhiChem Corporation, Shenzhen Dynanonic Co., Ltd.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $13.40B, beta of 0.80, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

002643.SZ currently shows total debt of N/A and beta of 0.80. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.valiant-cn.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.